ANTI-OBESITY MEDICATIONS FOR PEDS

CRAIG PRIMACK MD, FACP, FAAP, FOMA
SCOTTSDALE WEIGHT LOSS CENTER

Disclosures

- Currax Pharmaceuticals- Speaker
- Nestle Nutrition- Co-Medical Director
- Pri-Med CME- Speaker
- Gelesis Advisory Board Member

CRAIG PRIMACK MD, FACP, FAAP, FOMA SCOTTSDALE WEIGHT LOSS CENTER

THE COMPREHENSIVE APPROACH



WHAT MAKES WEIGHT MANAGEMENT SO DIFFICULT?

Insulin

Behavioral Triggers

Adiposity Signals

Satiation Signals

Hedonic Response

Emotional Triggers

Social Triggers
Habits

Biologic Regulators

Leptin

Adiponectin

Ghrelin

Orexin

GLP-1

PYY




2011 STUDY-- NEJM SUMITHRAN

CHANGED OUR UNDERSTANDING OF

LEPTIN AND GHRELIN

PHYSIOLOGIC RESPONSE TO A CALORIC DEFICIT

 Negative energy balance triggers a physiologic increase in hunger and decrease in satiety



WHY USE MEDICATIONS (AOMS)

Medication | Anti-obesity Medications

Adjunct to nutritional, physical activity, and behavioral therapies.

Objectives:

- **Treat disease**
 - Adiposopathy or sick fat disease (SFD)
 - Fat mass disease (FMD)
- Facilitate management of eating behavior
- Slow progression of weight gain/regain
- Improve the health, quality of life, and body weight of the patient with overweight or obesity
- May be an effective adjunct to bariatric surgery in enhancing weight loss or preventing weight regain

5-10%
weight loss
may improve
both metabolic
and fat mass
disease.

OBESITY IS A SERIOUS, CHRONIC AND TREATABLE DISEASE

- Medications should be prescribed chronically or not at all
- Treatment is effective only as long as it is continued
 - Discontinuation of treatment generally results in regain of the weight that was lost

PHARMACOTHERAPY!

- FDA Approved for Indication of Obesity: Pediatric and Adult
 - Phentermine/Topiramate
 - Phentermine
 - Liraglutide**
 - Semaglutide
 - Orlistat
 - Setmelanotide
- Patients > 18 years of Age
 - Naltrexone/Bupropion

- FDA Approved for Indication of Type 2 Diabetes Mellitus: Used off-label for indication of obesity
 - Tirzepatide
 - Metformin*
 - Exenatide
 - Dulaglutide
 - Liraglutide*
 - Semaglutide
- FDA Approved for Other Indications:
 Used off-label for indication of obesity
 - Topiramate
 - Lisdexamfetamine
 - Bupropion

PHENTERMINE

Mechanism of Action:

Sympathomimetic; works on hypothalamus

Considerations:

- Approved >16 years !/?
- Dose: 37.5mg tablets (1/2 to 1)
- also as: 8mg tablets (1/2-1 qd-tid; 15mg, 30mg, & 37.5mg capsules
- SE: stimulant; caution with active CAD
- DEA: Schedule 4 Controlled
- Approved 1959! with continuous use in the US
- Label: I2-week approval; longer term use is NECESSARY! (off-label recommendation)

Thomas et al. Obesity (online) 2015

Apovian, J Clin Endo Metab 2015

PHENTERMINE

- My First Choice for Most Patients
 - Inexpensive
 - Stood the test of time (1959)
 - Predictable results and SE
- Start a 37.5mg tablet but only half first thing in the am
- SE: For 2-3 nights, may lose sleep, may have dry mouth ("but helps you drink the water I want you to drink")
- If not lasting long enough, move start to between 9am -12pm and if late enough in day that hungry in the am, then add 2nd half to dosing regimen

PHENTERMINE/TOPIRAMATE ER

 Mechanism of action: Sympathomimetic (Mild Stimulant) effect on hypothalamus (Phentermine) + Topiramate (GABA system)

Benefits:

- more weight loss than phentermine alone (studies not performed head-to-head)
 - BMI change= -10.44% top dose; -8.11% points mid dose
- Great option for patient desiring one pill per day
- Generally well-tolerated
- Dose is 3.75/23, <u>7.5/46</u>, 11.25/69, <u>15/92</u>

Considerations:

- Requirement for women of child-bearing potential to use adequate contraception and perform monthly pregnancy testing. REMS: increase in cleft lip and palate (6/1000)
- Moderately Expensive
- Approved 2012
- DEA: Schedule 4 Controlled

PHENTERMINE/TOPIRAMATE ER

- Topiramate is a great add on to Phentermine
- With 4 doses- can titrate medication for effect
- Currently the most potent combo drug!
- Side Effects
 - Cleft Lip/Palate estimated at 6/1000
 - Paresthesias- nuisance
 - Word Recall- goes away in 48 hours if med stopped
 - Dysgeusia- Carbonated drinks taste "flat" or "metallic"
 - REMS: monthly pregnancy tests (does not have to be in office) and 2 forms of contraception recommended

LIRAGLUTIDE 3.0MG

Mechanism:

GLP-I Agonist (half life 13 hours)

Benefits:

- Long-acting appetite control vs stimulant class
- Extra benefit in those with pre-diabetes/diabetes (class available since 2010)
- Weight Loss over placebo: 7%

Considerations:

- Approved >12Y and T2DM >10Y (different max dose)
- Dose: start 0.6, 1.2, 1.8, 2.4 and 3 mg daily with weekly increase
- SE: GI related (nausea), delayed gastric emptying
- Warnings/REMS: Avoid if history of thyroid cancer (MTC), multiple endocrine neoplasia (MEN-2); Precaution/Warning if history of pancreatitis
- Limited use if patient does not have coverage for AOMs
- SC injection
- Approved 2015

LIRAGLUTIDE 3.0MG

- Have not used more than a few times since semaglutide has come out
- Consider combination with phentermine (off-label recommendation)
- Titration can be done slowly by using clicks each dosing interval is 10 clicks
- Use of antacids and H2 blockers may reduce associated nausea symptoms from gastroparesis

ORLISTAT

- Mechanism of Action:
 - Lipase inhibitor
- Considerations:
 - 120 mg tid, now OTC @60mg TID
 - Side Effects
 - Steatorrhea
 - Flatulence
- Interesting that in early 2000s this was \$140/month

ORLISTAT

- I do not use this drug
- Now OTC
- Steatorrhea and other embarrassing SE

SEMAGLUTIDE 2.4MG

- Titrate dose 0.25 SC weekly, 0.5, Img, I.7mg then 2.4mg
- MOA: GLP-I agonist
 - Central satiety, Decreases gastric emptying
- Contraindications: Pregnancy, Personal or FH of Medullary Thyroid Cancer/MEN2
- Precautions: acute pancreatitis, serious hypoglycemia with secretagogues, HR increase, Renal Impairment
- Common Adverse Reactions:
 - N/V, dyspepsia, constipation and diarrhea
 - Headache, dizziness, fatigue
 - Hypoglycemia, abd pain, increased lipase

SEMAGLUTIDE

- Very, Very popular right now Everywhere (social media)
- Can be quite expensive and very poor coverage (unless DM2)

SETMELANOTIDE

- FDA approved >6Y
- For Rare Genetic Causes of Obesity
 - Proopiomelanocortin (POMC) Deficiency
 - Proprotein Convertase I (PCSKI) deficiency
 - Leptin Receptor (LEPR) Deficiency
 - Bardet-Beidl Syndrome (BBS)
 - Other variants in POMC, PCSK I, LEPR or BBS


SETMELANOTIDE

- Mechanism: Melanocortin 4 (MC4R) receptor agonist
- Weight loss
 - LEPR -9.7%
 - POMC or PCSK1 -23.1% at one year
- SE: hyperpigmentation, GI, depression, dizziness, fatigue, HA, insomnia, vertigo and prolonged penile erections
- Once daily injection
- www.UncoveringRareObesity.com
 - Early onset, severe obesity--indication is <18 w/BMI >= 97th % and
 - Hyperphagia

CONTRAVE

- Indicated >18 years...
- Bupropion and Naltrexone ER
- Works on appetite center and cravings center
- Cost about ~\$105 without coverage

Percent Weight Loss



Information from package inserts, Apovian 2015, Greenway 2004, Wadden 2013, Astrup 2012.



OFF LABEL MEDICATIONS

FOR WEIGHT LOSS

METFORMIN

- May help improve adiposopathic disorders:
 - Insulin resistance
 - Polycystic ovarian syndrome
 - Fatty liver
 - Cardiovascular disease (especially when compared to sulfonylurea)
- May help treat complications of other concurrent drug treatments:
 - Antipsychotic-related weight gain
 - Human immunodeficiency virus (HIV) protease inhibitor-associated abnormalities (i.e., HIV lipodystrophy)
- May help reduce the overall cancer rate and help improve the treatment of multiple cancers:
 - Colon
 - Ovary
 - Lung
 - Breast
 - Prostate
- May reduce appetite with via multifactorial effects, such as enhancing the effects of gastrointestinal hormones applicable to weight loss (e.g., glucagon-like peptide-I, Peptide YY)
- May help facilitate long-term weight loss
- In addition to improving insulin sensitivity, metformin may also improve leptin sensitivity, reduce neuropeptide Y levels, and increase glucagon like peptide-I (GLP-I) activity (i.e., increased GLP-I levels and receptors).

TOPIRAMATE

- Can be used Solo (Studies were performed with phentermine/topiramate ER approval studies)
 - 25 or 50mg tabs
 - Week I- 25mg at night
 - Week 2 25mg am and night
 - If working, continue this dose
 - If needed,
 - Week 3 25 am and 50pm
 - Week 4 50mg bid (continuing dose)
 - Also, in some binge disorder patients
 - inexpensive

DISCLAIMER FOR INDIVIDUAL PATIENTS

- Everyone is different
- For every person that gains, another may lose
- None of these studies are done head-to-head




Figure 1. The 12-month weight change of individual study participants who completed the full study protocol of the A TO Z Study, by diet group, ordered from greatest loss to greatest gain. Each bar represents an individual study participant. Missing data for 12, 23, 24 and 22% for the Atkins, Zone, LEARN and Ornish groups, respectively.

MEDICATION RELATED WEIGHT GAIN

GENERAL CONCEPTS

- The medical literature is often contradictory regarding drug-induced weight gain
- Conditions treated may be associated with obesity (e.g. depression, diabetes mellitus, and hypertension)
- Changes in lifestyle brought on by these conditions
- Not every patient gains weight from medications associated with weight gain
- Some people actually lose weight on these drugs
- Some medications associated with weight gain may benefit eating disorders (ex: some SSRI's)

ANTIDEPRESSANTS

Antidepressants

May increase body weight (reports on body weight not alwavs consistent):

- Some tricyclic antidepressants (tertiary amines)
 - Amitriptyline
 - Doxepin
 - Imipramine
 - Dosulepin
- Some selective serotonin reuptake inhibitors (e.g. paroxetine, citalopram)
- Some selective serotonin and norepinephrine reuptake inhibitors (e.g., venlafaxine)
- Some irreversible monoamine oxidase inhibitors (e.g., isocarboxazid, phenelzine)
- Trazodone
- Mirtazapine
- Brexpiprazole

May decrease body weight:

- Bupropion
- Fluoxetine (variable)

Variable effects on body weight:

- Some tricyclic antidepressants (secondary amines)
 - Designamine
 - Nortriptyline
 - Protriptyline
- Some selective serotonin reuptake inhibitors
 - Escitalopram
 - Sertraline
- Some serotonin and norepinephrine re-uptake inhibitors
 - Desvenlafaxine
 - Duloxetine
- Some irreversible monoamine oxidase inhibitors (i.e., tranylcypromine)Some other serotonergic agents
- - Vortioxetine

MOOD STABILIZERS/MIGRANE MEDS

Mood Stabilizers

May increase body weight:

- Gabapentin
- Divalproex
- Lithium
- Valproate
- Vigabatrin
- Cariprazine
- Carbamazepine

Variable/neutral effects on body weight:

- Lamotrigine (sometimes reported to decrease body weight)
- Oxcarbazepine

Migraine Medications

May increase body weight:

- Amitriptyline
- Gabapentin
- Paroxetine
- Valproic acid
- Some beta-blockers

May decrease body weight:

- Topiramate
- Zonisamide

ANTI-PSYCHOTICS

Most consistently increase body weight:

Antipsychotics

- Clozapine Olanzapine
- Chloropromazine
- Brexpiprazole
- Iloperidone
- Lithium

- Quetiapine
- Risperidone
- Sertindole
- Trifluoperazine
- Zotepine

Neutral/variable effects on body weight:

- Amisulpride
- Aripiprazole
- Asenapine
- Cariprazine
- Haloperidol
- Loxipine
- Lurasidone
- Ziprasidone

- Paliperidone
- Perphenazine

HYPNOTICS

abt:

May increase body weight:

Diphenhydramine

Hypnotics

May have limited effects on body weight:

- Benzodiazepines
- Melatonergic hypnotics
- Trazodone

HORMONES

Hormones

May increase body weight:

Glucocorticoids

Variable effects on body weight:


- Progestin contraceptives
 - Injectable or implantable progestins may have greatest risk for weight gain
 - May be dependent upon the individual
- Testosterone
 - May reduce percent body fat and increase lean body mass, especially if used to replace testosterone deficiency in men

OBESITY: TREAT OR REFER



THANK YOU

- www. ScottsdaleWeightLoss.com
- <u>DrPrimack@ScottsdaleWeightLoss.com</u>
- www.DoctorPrimack.com
- IG:@DoctorPrimack



- Obesity Medicine Association
- www.ObesityMedicine.org
 - Clinician Finder
 - Pediatric Obesity Algorithm
 - 2 Conferences/year (spring and fall)
 - ABOM Review Course
 - OMAcademy